These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23907144)

  • 21. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment.
    Feigenbaum L; Scott BL; Moye MS; Nijhawan RI
    Dermatol Surg; 2017 Jul; 43(7):989-991. PubMed ID: 28002101
    [No Abstract]   [Full Text] [Related]  

  • 23. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma.
    Dubey AK; Dubey S; Handu SS; Qazi MA
    J Postgrad Med; 2013; 59(1):48-50. PubMed ID: 23525058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing hedgehog for the treatment of basal cell carcinoma.
    Harms KL; Dlugosz AA
    JAMA Dermatol; 2013 May; 149(5):607-8. PubMed ID: 23677088
    [No Abstract]   [Full Text] [Related]  

  • 25. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
    Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
    J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma.
    Eiger-Moscovich M; Reich E; Tauber G; Berliner O; Priel A; Ben Simon G; Elkader AA; Yassur I
    Am J Ophthalmol; 2019 Nov; 207():62-70. PubMed ID: 31077664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vismodegib.
    Meiss F; Zeiser R
    Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma.
    Wilkes GM
    Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):31-3. PubMed ID: 25375009
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma.
    Yin VT; Pfeiffer ML; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2013; 29(2):87-92. PubMed ID: 23446297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
    Keserü M; Green S; Dulz S
    Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
    Bayers S; Kapp DL; Beer KR; Slavin B
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.
    Lucero OM; Fitzmaurice S; Thompson C; Leitenberge J
    Dermatol Online J; 2018 Feb; 24(2):. PubMed ID: 29630158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib.
    Powell EM; Stratton JS; Shendrik I; Blalock TW
    Dermatol Surg; 2016 Jul; 42(7):904-7. PubMed ID: 27191782
    [No Abstract]   [Full Text] [Related]  

  • 34. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hedgehog hopes lifted by approval... and stung by failure.
    Allison M
    Nat Biotechnol; 2012 Mar; 30(3):203. PubMed ID: 22398601
    [No Abstract]   [Full Text] [Related]  

  • 36. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment.
    Nayyar PM; Chang ALS; Sarin K; Ratner D
    Dermatol Surg; 2019 Apr; 45(4):608-610. PubMed ID: 30045109
    [No Abstract]   [Full Text] [Related]  

  • 37. Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal cell carcinoma.
    Fosko SW; Chu MB; Mattox AR; Richart JM; Burkemper NM; Slutsky JB
    Dermatol Ther; 2015; 28(6):359-62. PubMed ID: 26114264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
    Meani RE; Lim SW; Chang AL; Kelly JW
    Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
    Sekulic A; Migden MR; Basset-Seguin N; Garbe C; Gesierich A; Lao CD; Miller C; Mortier L; Murrell DF; Hamid O; Quevedo JF; Hou J; McKenna E; Dimier N; Williams S; Schadendorf D; Hauschild A;
    BMC Cancer; 2017 May; 17(1):332. PubMed ID: 28511673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.